文献速递淋巴瘤

慢性淋巴细胞白血病中的IGH易位:临床病理特征与临床结局

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
PubMed 文献 · Am J Hematol · 2019-01-08

在梅奥诊所慢性淋巴细胞白血病(CLL)数据库中,2002年3月1日至2016年9月30日期间确诊3年内行FISH检测的1684例初治患者中,38例(2.2%)有IGH-BCL2易位、16例(0.9%)有IGH-BCL3易位。IGH-BCL3组5年需治疗概率和5年总生存均显著差于IGH-BCL2组和非IGH组。多因素分析显示IGH-BCL3易位与更短至首次治疗时间和更短总生存相关。

要点

  • 初治CLL中IGH-BCL2易位占2.2%,IGH-BCL3易位占0.9%。
  • IGH-BCL3组5年需治疗概率84%,高于IGH-BCL2组33%和非IGH组29%。
  • IGH-BCL3组5年总生存45%,短于IGH-BCL2组89%和非IGH组86%。

核心结论

  • 约3%的新诊断CLL患者携带IGH-BCL2或IGH-BCL3易位,IGH-BCL3易位患者具有独特的预后特征和结局。
  • 作者认为这些结果支持在新诊断CLL的常规FISH异常评估中加入IGH探针。

研究设计与样本

  • 利用梅奥诊所CLL数据库,纳入2002年3月1日至2016年9月30日期间确诊3年内行FISH检测的初治CLL患者1684例。
  • 比较IGH-BCL2易位组、IGH-BCL3易位组与非IGH组的预后特征、至首次治疗时间和总生存。

主要发现

  • 1684例患者中,38例(2.2%)有IGH-BCL2易位,16例(0.9%)有IGH-BCL3易位。
  • IGH-BCL3易位组较IGH-BCL2易位组和非IGH组更常见高和极高CLL国际预后指数。
  • 5年需治疗概率:IGH-BCL3组84% vs IGH-BCL2组33% vs 非IGH组29%(P < 0.0001)。
  • 5年总生存:IGH-BCL3组45% vs IGH-BCL2组89% vs 非IGH组86%(P < 0.0001)。
  • 多因素分析:IGH-BCL3易位与更短至首次治疗时间相关(HR = 2.7;P = 0.005),与更短总生存相关(HR = 5.5;P < 0.0001);IGH-BCL2易位对至首次治疗时间和总生存无影响。

关键数值与推荐

  • IGH-BCL3易位组5年需治疗概率84%,IGH-BCL2组33%,非IGH组29%(P < 0.0001)。
  • IGH-BCL3易位组5年总生存45%,IGH-BCL2组89%,非IGH组86%(P < 0.0001)。
  • IGH-BCL3易位与更短至首次治疗时间相关(HR = 2.7;P = 0.005),与更短总生存相关(HR = 5.5;P < 0.0001)。

临床怎么用

  • 作者认为这些结果支持在新诊断CLL的常规FISH异常评估中加入IGH探针。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence, clinicopathologic correlates, and outcomes of previously untreated chronic lymphocytic leukemia (CLL) patients with IGH-BCL2 and IGH-BCL3 translocations are not well known. Using the Mayo Clinic CLL database, we identified patients seen between March 1, 2002 and September 30, 2016 who had FISH testing performed within 3 years of CLL diagnosis. The prognostic profile, time to first therapy (TTT), and overall survival (OS) of patients with IGH-BCL2 and IGH-BCL3 translocation were compared to patients without these abnormalities (non-IGH group). Of 1684 patients who met the inclusion criteria, 38 (2.2%) had IGH-BCL2, and 16 (0.9%) had IGH-BCL3 translocation at diagnosis. Patients with IGH-BCL3 translocation were more likely to have high and very-high CLL-International Prognostic Index, compared to patients with IGH-BCL2 translocation and the non-IGH group. The 5-year probability of requiring therapy was significantly higher for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups (84% vs 33% vs 29%, respectively, P < 0.0001). The 5-year OS was significantly shorter for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups (45% vs 89% vs 86%, respectively, P < 0.0001). On multivariable analyses, IGH-BCL3 translocation was associated with a shorter TTT (hazard ratio [HR] = 2.7; P = 0.005) and shorter OS (HR = 5.5; P < 0.0001); IGH-BCL2 translocation did not impact TTT and OS. In conclusion, approximately 3% of all newly diagnosed CLL patients have either an IGH-BCL2 or IGH-BCL3 translocation. Patients with IGH-BCL3 translocations have a distinct prognostic profile and outcome. These results support the inclusion of an IGH probe during the routine evaluation of FISH abnormalities in newly diagnosed CLL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Fang H, Reichard KK, Rabe KG, et al. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. Am J Hematol. 2019. PMID: 30575108. doi:10.1002/ajh.25385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。